A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

NCT04398108 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Metastatic Breast Cancer

Interventions

DRUG: Margetuximab Margetuximab-IV

Sponsor

Zai Lab (Shanghai) Co., Ltd.